OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Patel on Mitigating CAR T-Cell Therapy­–Related CRS in Multiple Myeloma

September 16th 2021

Krina K. Patel, MD, MSc, discusses mitigating CAR T-cell therapy–related cytokine release syndrome in multiple myeloma.

Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer

September 16th 2021

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Dr. Rodriguez on the Role of Immunotherapy in ES-SCLC

September 16th 2021

Estelamari Rodriguez, MD, MPH, discusses the role of immunotherapy in extensive-stage small cell lung cancer.

Dr. Anderson on the Challenges Faced With CAR T-Cell Therapy in Myeloma

September 16th 2021

Larry Anderson, MD, PhD, discusses the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC

September 15th 2021

Collin Blakely MD, PhD, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Dr. Shah on the Current State of Cellular Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

Dr. Pecot on Selecting Between Available Targeted Therapies in NSCLC

September 15th 2021

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.

Dr. Kahl on Patient Selection for Intensive Vs Non-Intensive Treatment in MCL

September 15th 2021

Brad S. Kahl, MD, discusses patient selection for intensive vs non-intensive treatment strategies in mantle cell lymphoma.

Dr. Shah on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Dr. Ready on the Role of Frontline Chemoimmunotherapy in Lung Cancer

September 14th 2021

Neal E. Ready, MD, PhD, discusses the role of frontline chemoimmunotherapy in lung cancer.

Dr. Costa on the Patients Included in the OlympiA Trial in HER2- Breast Cancer

September 14th 2021

Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.

Dr. Marshall on Considerations for Third-Line Therapeutic Options in CRC

September 14th 2021

John L. Marshall, MD, discusses factors to consider in the third-line treatment setting for patients with colorectal cancer.

Dr. Mogal on Patient Selection for Cytoreductive Surgery in CRC

September 13th 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the importance of patient selection for cytoreductive surgery in colorectal cancer with peritoneal involvement.

Dr. Sborov on the Toxicities Associated With Novel Therapies in Multiple Myeloma

September 13th 2021

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

Dr. Patil on the Development of KRAS G12C Inhibitors in Lung Cancer

September 13th 2021

Pradnya D. Patil, MD, FACP, discusses the development of KRAS G12C inhibitors in lung cancer.

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

September 12th 2021

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Dr. Williams on the Rationale for the SunRISE-2 Trial in Muscle-Invasive Bladder Cancer

September 12th 2021

Stephen B. Williams, MD, discusses the rationale for the phase 3 SunRISE-2 trial in muscle-invasive bladder cancer.

Dr. Schjesvold on OCEAN Trial Takeaways With Melflufen in Relapsed/Refractory Myeloma

September 12th 2021

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.

Dr. Garon on the Efficacy of Datopotamab Deruxtecan in NSCLC

September 11th 2021

Edward B. Garon, MD, discusses the efficacy of datopotamab deruxtecan in patients with non–small cell lung cancer, as reported in the phase 1 TROPION-PanTumor01 trial.

Dr. Osarogiagbon on Geographic Disparities in Lung Cancer Mortality Rates in the United States

September 11th 2021

Raymond U. Osarogiagbon, MD, discusses geographic disparities in lung cancer mortality rates across the United States.

NEXT PAGE
PREVIOUS PAGE